© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Signal transduction systems and atrial fibrillation
aDivision of Cardiology, Department of Internal Medicine, University Hospital Magdeburg, Leipzigerstr. 44, 39120 Magdeburg, Germany
bInstitute of Experimental Internal Medicine, Department of Internal Medicine, University Hospital Magdeburg, Magdeburg, Germany
* Corresponding author. Tel.: +49-391-671-3203; fax: +49-391-671-3202 andreas.goette{at}medizin.uni-magdeburg.de
Cell communication, an essential component of integrated physiological function in multicellular organisms, is mediated largely through informational molecules, such as hormones and neurotransmitters. After binding to specific receptors, these first messengers activate intracellular signaling cascades and, thereby, translate extracellular messenger levels into intracellular events. Atrial fibrillation is associated with significant electrophysiological and structural alterations of atrial tissue. Most of these changes seem to be related to activation of signal transduction systems at the molecular atrial level. This review will describe the role and regulation of different signal transduction systems in fibrillating atria.
KEYWORDS AC, adenylyl cyclase; ACE, angiotensin-converting enzyme; ADAM, a disintegrin and metalloprotease; AF, atrial fibrillation; APA, aminopeptidase A; APB, aminopeptidase B; APN, alanyl-aminopeptidase; bFGF, basic fibroblast growth factor; BK, bradykinin; CPM, carboxypeptidase M; DAG, diacylglycerol; DPIV, dipeptidyl peptidase IV (CD26); ERK-1,-2, extracellular-signal regulated kinase-1,-2; FAK, focal adhesion kinase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; IL, interleukin; IP3, inositol trisphosphate; JAK2, janus kinase 2; JNK, c-jun terminal kinase; MAPK, mitogen-activated protein kinase; MEK-1,-2, Erk-activating kinase-1,-2; MKK, MAP kinase kinase; MKKK, MAP kinase kinase kinase; MMP, matrix metalloproteinase; NC, ADP-ribosyl cyclase; NEP, neutral endopeptidase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; Shc, sequence homology of collagen; SOD, superoxide dismutase; Sos, ‘son of sevenless’; STAT, signal transducer and activators of transcription; TGF-β, transforming growth factor β
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Goette Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke? Cardiovasc Res, August 1, 2009; 83(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ravens and E. Cerbai Role of potassium currents in cardiac arrhythmias Europace, October 1, 2008; 10(10): 1133 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Avila, I. M. Medina, E. Jimenez, G. Elizondo, and C. I. Aguilar Transforming growth factor-beta1 decreases cardiac muscle L-type Ca2+ current and charge movement by acting on the Cav1.2 mRNA Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H622 - H631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, B. J.J.M. Brundel, J. Lavoie, and S. Nattel Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs Cardiovasc Res, March 1, 2006; 69(4): 865 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Barth, S. Merk, E. Arnoldi, L. Zwermann, P. Kloos, M. Gebauer, K. Steinmeyer, M. Bleich, S. Kaab, M. Hinterseer, et al. Reprogramming of the Human Atrial Transcriptome in Permanent Atrial Fibrillation: Expression of a Ventricular-Like Genomic Signature Circ. Res., May 13, 2005; 96(9): 1022 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goette and U. Lendeckel Tachycardia-induced remodeling: atria and ventricles take a different route Cardiovasc Res, August 1, 2004; 63(2): 194 - 195. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pacifico and P. D. Henry Ablation for atrial fibrillation: are cures really achieved? J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1940 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Heidbuchel A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur. Heart J., December 1, 2003; 24(23): 2077 - 2078. [Full Text] [PDF]
|
|
|
|
|
|
H. U. Klein and A. Goette Blockade of atrial angiotensin II type 1 receptors: A novel antiarrhythmic strategy to prevent atrial fibrillation? J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2205 - 2206. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel Atrial Electrophysiology and Mechanisms of Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1_suppl): S5 - S11. [Abstract] [PDF]
|
|
|
|
|
|
I. Savelieva and A. John Camm Atrial fibrillation and heart failure: natural history and pharmacological treatment Europace, January 1, 2003; 5(s1): S5 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel, M. Allessie, and M. Haissaguerre Spotlight on atrial fibrillation--the 'complete arrhythmia' Cardiovasc Res, May 1, 2002; 54(2): 197 - 203. [Full Text] [PDF]
|
|